CTRI/2014/09/005074进行中（未招募）3 期
Prospective, open-label, uncontrolled, phase III study to assess the efficacy and safety of Octafibrin for on-demand treatment of acute bleeding and to prevent bleeding during and after surgery in subjects with congenital fibrinogen deficiency.
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Aged >=12 years.
- •2.Documented diagnosis of congenital fibrinogen deficiency, expected to require on-demand treatment for bleeding or surgical prophylaxis:
- •ï?Fibrinogen deficiency manifested as afibrinogenaemia or severe hypofibrinogenaemia.
- •ï?Historical plasma fibrinogen activity of <50 mg/dL or levels below the limit of detection of the local assay method.
- •3.Having an acute bleeding episode (spontaneous or after trauma) or planning to undergo elective surgery.
- •4.Informed consent signed by the subject or legal guardian.
排除标准
- •1.Life expectancy <6 months.
- •2.Bleeding disorder other than congenital fibrinogen deficiency, including dysfibrinogenaemia.
- •3.Prophylactic treatment with a fibrinogen concentrate.
- •4.Treatment with:
- •ï?Any fibrinogen concentrate or other fibrinogen-containing blood product within 2 weeks prior to start of treatment for the bleeding episode or surgery.
- •ï?Any coagulation-active drug (i.e., non-steroidal anti-inflammatory drugs, warfarin, coumarin derivatives, platelet aggregation inhibitors) within 1 week prior to start of treatment for the bleeding episode or surgery, or as a planned or expected medication during the time period from Day 1 until 24 hours
- •(i.e., 1 day) after the last Octafibrin infusion.
- •5.Presence or history of:
- •ï?Hypersensitivity to study medication.
- •ï?Deep vein thrombosis or pulmonary embolism within 1 year prior to start of treatment for the bleeding episode or surgery.
- •ï?Arterial thrombosis within 1 year prior to start of treatment for the bleeding episode or surgery
- •ï?Hypersensitivity to human plasma proteins.
- •ï?Oesophageal varicose bleeding.
- •ï?End-stage liver disease (i.e., Child-Pugh score B or C).
- •6.Pregnant women within the first 20 weeks of gestation.
- •7.Currently breast-feeding.
- •8.Known positive HIV infection with a viral load >200 particles/μL or >400,000 copies/mL.
- •9.Polytrauma 1 year prior to start of treatment for the bleeding episode or surgery.
- •10.Diagnosis or suspicion of a neutralizing anti-fibrinogen inhibitor currently or any time in the past.
- •11.Acute or chronic medical condition which may, in the opinion of investigator,
- •affect the conduct of the study, including
- •ï?Subjects receiving immune-modulating drugs (other than anti-retroviral chemotherapy) such as alpha-interferon, prednisone (equivalent to >10 mg/day), or similar drugs at study start.
- •ï?Subjects having evidence or a history (within the previous 12 months) of abuse of any licit or illicit drug substance.
- •12.Participation in another interventional clinical study currently or during the past 4 weeks.
研究者
相似试验
进行中（未招募）
3 期
To study the effect of Octafibrin (i.e. human plasma fibrinogen concentrate, which is a product derived from blood) in paediatric subjects with congenital fibrinogen deficiency (a rare bleeding disorder).CTRI/2015/07/005953Octapharma AG4
进行中（未招募）
1 期
A study of the effectiveness and safety of Octafibrin, a replacement for fibrinogen, in patients with inherited fibrinogen deficiency causing episodes of bleeding.EUCTR2011-002419-27-GBOctapharma AG25
已完成
3 期
The assessment of the efficacy and safety of Fibrinogen ( Octafibrin) in subjects with congenital fibrinogen deficiency”congenital Afibrinogenemia.Hereditary deficiency of other clotting factorsIRCT2014112420051N4Octapharma AG24
进行中（未招募）
1 期
A study of the effectiveness and safety of Octafibrin, a replacement for fibrinogen, in patients with inherited fibrinogen deficiency causing episodes of bleeding.EUCTR2011-002419-27-BGOctapharma AG24
已完成
3 期
The effect of haemostatic factor,Octafibrin in congenital afibrinogenemiaIRCT2014112320051N3Octapharma3